| [1] |
TANAKA A. Current understanding of primary biliary cholangitis[J]. Clin Mol Hepatol, 2021, 27( 1): 1- 21. DOI: 10.3350/cmh.2020.0028. |
| [2] |
FARZAM K, GIBB C. Novel antibodies for anti-mitochondrial antibody-negative primary biliary cholangitis[J]. Biomark Med, 2023, 17( 9): 455- 457. DOI: 10.2217/bmm-2023-0143. |
| [3] |
WASIK U, KEMPINSKA-PODHORODECKA A, BOGDANOS DP, et al. Enhanced expression of miR-21 and miR-150 is a feature of anti-mitochondrial antibody-negative primary biliary cholangitis[J]. Mol Med, 2020, 26( 1): 8. DOI: 10.1186/s10020-019-0130-1. |
| [4] |
DENG CW, WANG L, FEI YY, et al. Exploring pathogenesis of primary biliary cholangitis by proteomics: A pilot study[J]. World J Gastroenterol, 2017, 23( 48): 8489- 8499. DOI: 10.3748/wjg.v23.i48.8489. |
| [5] |
CANÇADO GGL, BRAGA MH, FERRAZ MLG, et al. Anti-mitochondrial antibody-negative primary biliary cholangitis is part of the same spectrum of classical primary biliary cholangitis[J]. Dig Dis Sci, 2022, 67( 7): 3305- 3312. DOI: 10.1007/s10620-021-07122-y. |
| [6] |
CHASCSA DM, LINDOR KD. Antimitochondrial antibody-negative primary biliary cholangitis: Is it really the same disease?[J]. Clin Liver Dis, 2018, 22( 3): 589- 601. DOI: 10.1016/j.cld.2018.03.009. |
| [7] |
ZANDANELL S, STRASSER M, FELDMAN A, et al. Similar clinical outcome of AMA immunoblot-M2-negative compared to immunoblot-positive subjects over six years of follow-up[J]. Postgrad Med, 2021, 133( 3): 291- 298. DOI: 10.1080/00325481.2021.1885945. |
| [8] |
JOHN BV, DAHMAN B, DENG YY, et al. Rates of decompensation, hepatocellular carcinoma and mortality in AMA-negative primary biliary cholangitis cirrhosis[J]. Liver Int, 2022, 42( 2): 384- 393. DOI: 10.1111/liv.15079. |
| [9] |
CRISTOFERI L, GERUSSI A, INVERNIZZI P. Anti-gp210 and other anti-nuclear pore complex autoantibodies in primary biliary cholangitis: What we know and what we should know[J]. Liver Int, 2021, 41( 3): 432- 435. DOI: 10.1111/liv.14791. |
| [10] |
BECK M, HURT E. The nuclear pore complex: Understanding its function through structural insight[J]. Nat Rev Mol Cell Biol, 2016, 18( 2): 73- 89. DOI: 10.1038/nrm.2016.147. |
| [11] |
YANG Z, WANG XY, RAN Y, et al. Research progress on clinical features and pathogenesis of anti-gp210-positive primary biliary cholangitis[J]. Chin J Intern Med, 2024, 63( 9): 901- 906. DOI: 10.3760/cma.j.cn112138-20230901-00104. |
| [12] |
ZHANG JH, LI SL. Production mechanism and detection value of anti-gp210 antibody in primary biliary cholangitis[J]. J Clin Hepatol, 2022, 38( 6): 1416- 1419. DOI: 10.3969/j.issn.1001-5256.2022.06.041. |
| [13] |
WANG C, ZHENG XD, JIANG P, et al. Genome-wide association studies of specific antinuclear autoantibody subphenotypes in primary biliary cholangitis[J]. Hepatology, 2019, 70( 1): 294- 307. DOI: 10.1002/hep.30604. |
| [14] |
JASKOWSKI TD, NANDAKUMAR V, NOVIS CL, et al. Presence of anti-gp210 or anti-sp100 antibodies in AMA-positive patients may help support a diagnosis of primary biliary cholangitis[J]. Clin Chim Acta, 2023, 540: 117219. DOI: 10.1016/j.cca.2023.117219. |
| [15] |
HALDAR D, JANMOHAMED A, PLANT T, et al. Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis[J]. Liver Int, 2021, 41( 3): 535- 544. DOI: 10.1111/liv.14688. |
| [16] |
BAUER A, HABIOR A, GAWEL D. Diagnostic and clinical value of specific autoantibodies against kelch-like 12 peptide and nuclear envelope proteins in patients with primary biliary cholangitis[J]. Biomedicines, 2022, 10( 4): 801. DOI: 10.3390/biomedicines10040801. |
| [17] |
de LISO F, MATINATO C, RONCHI M, et al. The diagnostic accuracy of biomarkers for diagnosis of primary biliary cholangitis(PBC) in anti-mitochondrial antibody(AMA)-negative PBC patients: A review of literature[J]. Clin Chem Lab Med, 2017, 56( 1): 25- 31. DOI: 10.1515/cclm-2017-0249. |
| [18] |
BAUER A, HABIOR A. Detection of autoantibodies against nucleoporin p62 in sera of patients with primary biliary cholangitis[J]. Ann Lab Med, 2019, 39( 3): 291- 298. DOI: 10.3343/alm.2019.39.3.291. |
| [19] |
ZÜCHNER D, STERNSDORF T, SZOSTECKI C, et al. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis[J]. Hepatology, 1997, 26( 5): 1123- 1130. DOI: 10.1002/hep.510260506. |
| [20] |
ZHU YJ, LI J, LIU YG, et al. Role of biochemical markers and autoantibodies in diagnosis of early-stage primary biliary cholangitis[J]. World J Gastroenterol, 2023, 29( 34): 5075- 5081. DOI: 10.3748/wjg.v29.i34.5075. |
| [21] |
GRANITO A, MURATORI L, TOVOLI F, et al. Autoantibodies to speckled protein family in primary biliary cholangitis[J]. Allergy Asthma Clin Immunol, 2021, 17( 1): 35. DOI: 10.1186/s13223-021-00539-0. |
| [22] |
WANG PR, BENHENDA S, WU HY, et al. RING tetramerization is required for nuclear body biogenesis and PML sumoylation[J]. Nat Commun, 2018, 9( 1): 1277. DOI: 10.1038/s41467-018-03498-0. |
| [23] |
LEVY C, BOWLUS CL. Role of antinuclear antibodies in primary biliary cholangitis[J]. Am J Gastroenterol, 2020, 115( 10): 1604- 1606. DOI: 10.14309/ajg.0000000000000765. |
| [24] |
PAPAMICHALIS PA, ZACHOU K, PAPAMICHALI RA, et al. Promyelocytic leukemia antigen expression: A histological marker for primary biliary cholangitis diagnosis?[J]. J Transl Int Med, 2021, 9( 1): 43- 51. DOI: 10.2478/jtim-2021-0008. |
| [25] |
ZHOU YG, ZHANG Q, ZHAO ZQ, et al. Targeting kelch-like(KLHL) proteins: Achievements, challenges and perspectives[J]. Eur J Med Chem, 2024, 269: 116270. DOI: 10.1016/j.ejmech.2024.116270. |
| [26] |
SHI XX, XIANG SF, CAO J, et al. Kelch-like proteins: Physiological functions and relationships with diseases[J]. Pharmacol Res, 2019, 148: 104404. DOI: 10.1016/j.phrs.2019.104404. |
| [27] |
NORMAN GL, YANG CY, OSTENDORFF HP, et al. Anti-kelch-like 12 and anti-hexokinase 1: Novel autoantibodies in primary biliary cirrhosis[J]. Liver Int, 2015, 35( 2): 642- 651. DOI: 10.1111/liv.12690. |
| [28] |
NORMAN GL, REIG A, VIÑAS O, et al. The prevalence of anti-hexokinase-1 and anti-kelch-like 12 peptide antibodies in patients with primary biliary cholangitis is similar in Europe and North America: A large international, multi-center study[J]. Front Immunol, 2019, 10: 662. DOI: 10.3389/fimmu.2019.00662. |
| [29] |
LIU ZY, XU LS, LIU B. Detection of anti-kelch-like 12 and anti-hexokinase 1 antibodies in primary biliary cholangitis patients in China[J]. Rev Esp Enferm Dig, 2021, 113( 8): 585- 590. DOI: 10.17235/reed.2020.7483/2020. |
| [30] |
REIG A, NORMAN GL, GARCIA M, et al. Novel anti-hexokinase 1 antibodies are associated with poor prognosis in patients with primary biliary cholangitis[J]. Am J Gastroenterol, 2020, 115( 10): 1634- 1641. DOI: 10.14309/ajg.0000000000000690. |
| [31] |
SMYTH SS, KRAEMER M, YANG LP, et al. Roles for lysophosphatidic acid signaling in vascular development and disease[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2020, 1865( 8): 158734. DOI: 10.1016/j.bbalip.2020.158734. |
| [32] |
YANG YF, LIU BQ, ZANG B, et al. Autotaxin: A Potential biomarker for primary biliary cholangitis[J]. Heliyon, 2023, 10( 1): e23438. DOI: 10.1016/j.heliyon.2023.e23438. |
| [33] |
MAGKRIOTI C, GALARIS A, KANELLOPOULOU P, et al. Autotaxin and chronic inflammatory diseases[J]. J Autoimmun, 2019, 104: 102327. DOI: 10.1016/j.jaut.2019.102327. |
| [34] |
WANG Z, LI YX, REN LS, et al. Clinical performance of AMA-M2, anti-gp210 and anti-sp100 antibody levels in primary biliary cholangitis: When detected by multiplex bead-based flow fluorescent immunoassay[J]. Immun Inflamm Dis, 2024, 12( 1): e1161. DOI: 10.1002/iid3.1161. |
| [35] |
LAMINE Z BEN, JAZIA I BEN, AHMED M BEN, et al. Anti-gp210 and anti-Sp100 antibodies in primary biliary cholangitis[J]. Arab J Gastroenterol, 2021, 22( 4): 316- 320. DOI: 10.1016/j.ajg.2021.05.006. |
| [36] |
VILLALTA D, SEAMAN A, TIONGSON M, et al. Evaluation of a novel extended automated particle-based multi-analyte assay for the detection of autoantibodies in the diagnosis of primary biliary cholangitis[J]. Clin Chem Lab Med, 2020, 58( 9): 1499- 1507. DOI: 10.1515/cclm-2020-0122. |
| [37] |
GRANITO A, YANG WH, MURATORI L, et al. PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis[J]. Am J Gastroenterol, 2010, 105( 1): 125- 131. DOI: 10.1038/ajg.2009.596. |
| [38] |
ZHANG YP, ZHENG JK. Functions of immune checkpoint molecules beyond immune evasion[J]. Adv Exp Med Biol, 2020, 1248: 201- 226. DOI: 10.1007/978-981-15-3266-5_9. |
| [39] |
GAO XZ, WANG XM, GUAN YZ, et al. Soluble immune checkpoints are elevated in patients with primary biliary cholangitis[J]. Eur J Med Res, 2023, 28( 1): 477. DOI: 10.1186/s40001-023-01419-6. |
| [40] |
HADLEY T, GILLESPIE S, ESPINOZA H, et al. Soluble PD1 levels are increased with disease activity in paediatric onset autoimmune hepatitis and inflammatory bowel disease[J]. Autoimmunity, 2020, 53( 5): 253- 260. DOI: 10.1080/08916934.2020.1755964. |
| [41] |
CHENG A, HOLLAND SM. Anti-cytokine autoantibodies: Mechanistic insights and disease associations[J]. Nat Rev Immunol, 2023, 24( 3): 161- 177. DOI: 10.1038/s41577-023-00933-2. |
| [42] |
HOWE HS, LEUNG BPL. Anti-cytokine autoantibodies in systemic lupus erythematosus[J]. Cells, 2019, 9( 1): 72. DOI: 10.3390/cells9010072. |
DownLoad: